Early Biomarker Changes Predict MASH Resolution with Resmetirom
Noninvasive blood and imaging tests may track treatment efficacy without requiring liver biopsies.
1Predictive Biomarker Analysis
An exploratory analysis of the phase III MAESTRO-NASH trial indicates that early changes in specific blood and imaging biomarkers correlate with long-term MASH resolution. Researchers observed that markers measured between weeks 12 and 16 successfully predicted fibrosis improvement at week 52, offering a potential noninvasive pathway for monitoring patient treatment responses.
2Key Diagnostic Indicators
The study highlighted several critical markers, including alanine aminotransferase levels, magnetic resonance elastography liver stiffness, and MRI-proton density fat fraction. Additionally, PRO-C3, a biomarker associated with active fibrogenesis, showed significant correlation with clinical outcomes. These findings suggest that clinicians can track therapeutic progress without relying on invasive liver biopsy procedures.
3Statistical Significance Observed
Statistical analysis revealed odds ratios ranging from 2.03 to 8.83 for the identified biomarkers, all achieving high significance with P values under 0.001. These associations remained robust even after researchers adjusted for patient weight loss. Resmetirom treatment consistently outperformed the placebo group in achieving these early, favorable biomarker response thresholds.
4Clinical Monitoring Rationale
Dr. Rohit Loomba emphasized that while liver biopsies confirmed trial results, they are rarely performed in routine clinical practice to assess drug efficacy. Identifying early, noninvasive signals allows physicians to evaluate if a patient is responding to resmetirom therapy effectively, ensuring better management of noncirrhotic MASH patients with F2 or F3 fibrosis.
5Regulatory Approval Context
The FDA granted accelerated approval for resmetirom, a liver-directed thyroid hormone receptor-selective agonist, for treating noncirrhotic MASH. This approval was contingent on diet and exercise integration. The current exploratory analysis aims to bridge the gap between trial-based biopsy confirmation and practical, real-world clinical monitoring for patients undergoing this specific pharmacological intervention.
6Data Integrity Concerns
During the Liver Meeting presentation, Dr. David Goldberg raised questions regarding data integrity following a whistleblower lawsuit. Michael Charlton, a former Madrigal Pharmaceuticals executive, alleged he was forced to resign after raising safety concerns about the drug. Madrigal Pharmaceuticals has formally disputed these allegations, maintaining the integrity of their clinical development process.
7Sustained Response Patterns
Beyond predicting week 52 outcomes, the study found that patients treated with resmetirom experienced a shortened time to achieve sustained responses across all four tested biomarkers. This accelerated improvement suggests that the drug's mechanism of action may provide earlier physiological benefits than previously documented, potentially improving long-term prognosis for MASH patients.
8Future Clinical Implications
The ability to utilize clinically available biomarkers to predict histological success represents a shift in hepatology practice. By validating these noninvasive tools, the medical community moves closer to standardized, patient-friendly monitoring protocols. Future efforts will likely focus on confirming these predictive models across broader, more diverse patient populations in real-world settings.
Original article: MedPage Today — Early Biomarker Changes Predict MASH Resolution with Resmetirom